Literature DB >> 6693894

Passive transfer of Lambert-Eaton myasthenic syndrome in mice: decreased rates of resting and evoked release of acetylcholine from skeletal muscle.

B Lang, P C Molenaar, J Newsom-Davis, A Vincent.   

Abstract

Mice were injected for 1-2 months daily with 10 mg immunoglobulin G (IgG) from four patients with Lambert-Eaton myasthenic syndrome (LEMS); control mice were injected with pooled human IgG from normal donors. Gastrocnemius muscles were homogenised for the assay of acetylcholine (ACh), choline acetyltransferase (ChAT), and cholinesterase (ChE). The ACh, ChAT, and ChE contents of gastrocnemius muscles from "LEMS mice" were about the same as the control values, which were 180 pmol, 40 nmol X h-1 (37 degrees C), and 15 mumol X h-1 (37 degrees C), respectively. Hemidiaphragms were treated with an irreversible ChE inhibitor (Soman) and incubated at 20 degrees C for estimation of ACh release. Resting ACh release from experimental muscles was reduced by about 25% (P2 less than 0.05) and the release evoked by 3 s-1 nervous stimulation by 50% (P2 less than 0.05). On the other hand, 50 mM KCl-induced transmitter release was not abnormal in LEMS mice. The findings indicate that IgG antibody from patients with LEMS may bind to nerve terminal determinants that are involved in quantal and nonquantal ACh release.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693894     DOI: 10.1111/j.1471-4159.1984.tb02733.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Authors:  Stephen D Meriney; Tyler B Tarr; Kristine S Ojala; Man Wu; Yizhi Li; David Lacomis; Adolfo Garcia-Ocaña; Mary Liang; Guillermo Valdomir; Peter Wipf
Journal:  Ann N Y Acad Sci       Date:  2017-11-10       Impact factor: 5.691

2.  Circulating T cell subsets in the Lambert-Eaton myasthenic syndrome.

Authors:  S A Robb; T J Bowley; H N Willcox; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

Review 3.  Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1985

Review 4.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

5.  Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.

Authors:  Tyler B Tarr; David Lacomis; Stephen W Reddel; Mary Liang; Guillermo Valdomir; Michael Frasso; Peter Wipf; Stephen D Meriney
Journal:  J Physiol       Date:  2014-07-11       Impact factor: 5.182

6.  Blockade of acetylcholine release at the motor endplate by a polypeptide from the venom of Phoneutria nigriventer.

Authors:  C Souccar; M do C Gonçalo; A J Lapa; L R Troncone; I Lebrun; F Magnoli
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

7.  Surplus acetylcholine and acetylcholine release in the rat diaphragm.

Authors:  P C Molenaar; B S Oen; R L Polak; A L van der Laaken
Journal:  J Physiol       Date:  1987-04       Impact factor: 5.182

8.  Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome.

Authors:  Tyler B Tarr; Waqas Malick; Mary Liang; Guillermo Valdomir; Michael Frasso; David Lacomis; Stephen W Reddel; Adolfo Garcia-Ocano; Peter Wipf; Stephen D Meriney
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

Review 9.  Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States.

Authors:  Scott P Ginebaugh; Yomna Badawi; Tyler B Tarr; Stephen D Meriney
Journal:  Biomolecules       Date:  2022-05-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.